Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous IL-7Ra-expressing Tris-CAR T cells

A preparation of autologous T lymphocytes that have been genetically modified and lentivirally transduced to express a dual-target chimeric antigen receptor (CAR) and a truncated form of the cytokine receptor interleukin-7 (IL-7) receptor alpha (IL-7Ra), with potential immunostimulating and antineoplastic activities. Upon administration, autologous IL-7Ra-expressing Tris-CAR T cells target and bind to tumor cells expressing the targets, thereby inducing selective toxicity in these tumor cells. In addition, as IL-7/IL-7Ra-mediated signaling promotes the proliferation and survival of T cells, these tumor re-directed T cells may show enhanced expansion, survival and cytotoxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous inverse-correlated dual-target truncated IL7Ra-modified CAR-expressing T lymphocytes
autologous Tris-CAR-T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search